Cobitolimod

Drug Profile

Cobitolimod

Alternative Names: Antisense oligonucleotide NF-KB-p65; DIMS 0150; Kappaproct

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator InDex Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Genetic transcription modulators; NF-kappa B inhibitors; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ulcerative colitis
  • Phase I Brain oedema

Most Recent Events

  • 14 Mar 2017 InDex Pharmaceuticals receives patent allowance for cobitolimod in USA
  • 03 Nov 2016 InDex Pharmaceuticals has patent protection for cobitolimod in USA
  • 03 Nov 2016 InDex Pharmaceuticals has patents pending for cobitolimod in Europe, Japan and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top